<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Juvenile xanthogranuloma (JXG)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Juvenile xanthogranuloma (JXG)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Juvenile xanthogranuloma (JXG)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonal D Shah, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Moise L Levy, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H12028554">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Juvenile xanthogranuloma (JXG) is a benign, proliferative disorder belonging to the broad group of non-Langerhans cell histiocytoses and is typically a disorder of early childhood [
         <a href="#rid1">
          1
         </a>
         ]. JXG presents in the first two years of life as a solitary, reddish or yellowish skin papule or nodule  (
         <a class="graphic graphic_picture graphicRef69122" href="/z/d/graphic/69122.html" rel="external">
          picture 1D
         </a>
         ), most often on the head, neck, or upper trunk. Extracutaneous or systemic forms are exceedingly rare and can be associated with considerable morbidity.
        </p>
        <p>
         An overview of JXG will be presented here. Langerhans cell histiocytosis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8385.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12028561">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         JXG is the most common of the non-Langerhans cell histiocytoses [
         <a href="#rid2">
          2
         </a>
         ]. The incidence is unknown. In a large tumor registry spanning 35 years, JXG accounted for 129 of 24,600 pediatric tumors (0.5 percent) [
         <a href="#rid3">
          3
         </a>
         ]. However, this figure may be an underestimate of the relative frequency of JXG since many cases are diagnosed on clinical grounds without histologic confirmation. In a survey of 122 dermatologists with an average of 12 years of practice, 2371 cases of JXG were reported (an average of less than two cases per dermatologist per year), and only seven cases had ocular involvement [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The median ages of onset in two large case series were 5 months (range 0 to 244 months) and 1 year (range 0 to 20 years) [
         <a href="#rid3">
          3,5
         </a>
         ]. The male-to-female ratio was approximately 1.4:1.
        </p>
        <p class="headingAnchor" id="H12028568">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cause of JXG is unknown. All histiocytoses arise from CD34
         <sup>
          +
         </sup>
         stem cells that develop, based on the cytokine milieu, into CD14
         <sup>
          +
         </sup>
         or CD14
         <sup>
          -
         </sup>
         cells. Langerhans cells and Langerhans cell histiocytoses derive from CD14
         <sup>
          -
         </sup>
         cells. CD14
         <sup>
          +
         </sup>
         cells may become monocyte/macrophage lineage or dermal/interstitial dendrocytes, the latter considered to be the precursor cell of non-Langerhans cell histiocytoses [
         <a href="#rid2">
          2,6
         </a>
         ].
        </p>
        <p>
         A genomic analysis with molecular inversion probe array searching for copy number variation or loss of heterozygosity in 21 cases of JXG found that most solitary, cutaneous JXGs (19 of 21) lacked identifiable genetic changes [
         <a href="#rid7">
          7
         </a>
         ]. Genomic alterations appear more common in the setting of systemic JXG. A retrospective study showed that 35 percent of systemic JXGs had
         <em>
          ALK
         </em>
         translocations and 17 percent had
         <em>
          BRAF
         </em>
         V600E mutations (these two molecular alterations were mutually exclusive) [
         <a href="#rid8">
          8
         </a>
         ]. In a series of 12 JXG cases with systemic involvement, seven had mutations in several MAPK pathway genes, including
         <em>
          ARAF
         </em>
         ,
         <em>
          KRAS
         </em>
         ,
         <em>
          MAP2K1
         </em>
         , and
         <em>
          NRAS
         </em>
         [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H432992506">
         <span class="h1">
          PATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classic histology of JXG shows a mixed dermal infiltrate of mononuclear cells, multinucleated giant cells with or without the features of Touton giant cells (characterized by a ring or wreath of nuclei surrounded by a foamy cytoplasm), and spindle cells. Lymphocytes, eosinophils, neutrophils, and mast cells can be seen. The lesion is nonencapsulated but well demarcated, with dense sheets of cells infiltrating the dermis and the upper portion of the subcutaneous fat. The epidermis and adnexae are spared, though the epidermis can be thinned and, rarely, ulcerated.
        </p>
        <p>
         The microscopic appearance depends upon the age of the lesion. Early JXG shows only histiocytes or spindle-shaped fibrohistiocytic cells minimally lipidized. More mature JXG shows foamy, lipid-laden, vacuolated mononuclear cells and Touton giant cells. Regressing lesions show progressive replacement by fibrous tissue [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Immunostaining is important in establishing the diagnosis. JXG stains positively for factor XIIIa, a marker of interstitial dendrocytes, CD68, CD163, CD14, and fascin. A retrospective study of 77 JXGs showed positive staining for CD11c (a marker for macrophages, with expression limited to hematopoietic cells) in 97 percent of cases and positive staining for CD4 (which is expressed in a subset of monocyte and macrophage cells) in 100 percent of cases [
         <a href="#rid11">
          11
         </a>
         ]. Stains for S100 and CD1a, the latter of which is specific for Langerhans cells, are negative.
        </p>
        <p class="headingAnchor" id="H12028575">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3852509612">
         <span class="h2">
          Age of onset and lesion distribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         Between 40 and 70 percent of JXGs arise in the first year of life [
         <a href="#rid10">
          10
         </a>
         ]. In a series of 147 children, the median age of onset was 15.5 months, with 69 percent occurring before the age of two years [
         <a href="#rid12">
          12
         </a>
         ]. Rarely, JXG may be present at birth [
         <a href="#rid13">
          13
         </a>
         ]. In a retrospective study of 44 patients with JXG, only one (2.3 percent) was congenital [
         <a href="#rid14">
          14
         </a>
         ]. In a review of 47 cases of congenital JXG, 66 percent presented with isolated cutaneous involvement, and 34 percent presented with systemic involvement [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         In large case series, the lesion distribution was as follows [
         <a href="#rid3">
          3-5,12,16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Solitary skin lesion – 67 to 76 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple skin lesions – 7 to 10 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Superficial or deep soft tissue lesions – 15 to 16 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic involvement (with or without skin lesions) – 4 to 5 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eye involvement (with or without skin lesions) – 0 to 0.3 percent
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2265103523">
         <span class="h2">
          Cutaneous lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         JXG typically presents as a reddish, yellowish, or brown papule, plaque, or nodule  (
         <a class="graphic graphic_picture graphicRef69122" href="/z/d/graphic/69122.html" rel="external">
          picture 1D
         </a>
         ). The lesions are usually solitary  (
         <a class="graphic graphic_picture graphicRef68132 graphicRef81386 graphicRef59377 graphicRef69122" href="/z/d/graphic/68132.html" rel="external">
          picture 1A-D
         </a>
         and
         <a class="graphic graphic_picture graphicRef139414" href="/z/d/graphic/139414.html" rel="external">
          picture 2
         </a>
         ), but multiple lesions  (
         <a class="graphic graphic_picture graphicRef68597 graphicRef81058" href="/z/d/graphic/68597.html" rel="external">
          picture 3A-B
         </a>
         ) can occur.
        </p>
        <p>
         A size of 0.5 to 2 cm is typical. Lesions &gt;2 cm (giant JXG) are rare. The lesions can occur in any location and are most common on the head, neck, and upper trunk.
        </p>
        <p>
         Early lesions tend to be more reddish and raised, but as they mature and become progressively more lipidized, they appear more yellow and will often flatten. Fine telangiectasias occasionally can be seen overlying the lesion, and extracutaneous and systemic involvement may occur. All organs and systems can be affected. (See
         <a class="local">
          'Extracutaneous and systemic involvement'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3482244985">
         <span class="h2">
          Extracutaneous and systemic involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common extracutaneous presentation of JXG is a solitary nodule or mass in the subcutaneous or deep soft tissues [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Systemic involvement is rare and tends to occur in very young children, with a median age of onset of nine months [
         <a href="#rid17">
          17
         </a>
         ]. In a review of nearly 3000 published cases, systemic involvement occurred in 0.75 percent of patients [
         <a href="#rid16">
          16
         </a>
         ]. In another study of 456 cases of biopsy-confirmed JXG, systemic involvement was observed in 23 patients (5 percent), of which 15 had cutaneous lesions as well [
         <a href="#rid8">
          8
         </a>
         ]. Compared with those with cutaneous involvement only, those with systemic involvement often had multiple skin papules or nodules with ≥2 locations or giant cutaneous masses [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         In a systematic review that included 159 patients with systemic JXG, the most commonly involved site was the central nervous system (41 percent), followed by the liver (31 percent), the lung (19 percent), and the eye (18 percent) [
         <a href="#rid17">
          17
         </a>
         ] (see
         <a class="local">
          'Ocular juvenile xanthogranuloma'
         </a>
         below). Lesions may also occur in the spleen, lymph nodes, bones, kidneys, and gastrointestinal tract and may or may not be associated with cutaneous lesions [
         <a href="#rid1">
          1,5,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12028582">
         <span class="h2">
          Ocular juvenile xanthogranuloma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eye involvement is rare. In a series of 2949 cases, the prevalence of ocular JXG was 0.2 percent [
         <a href="#rid16">
          16
         </a>
         ]. Ocular JXG typically occurs in young children (&lt;2 years) and is associated with coexistent cutaneous lesions in approximately one-third of the cases [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The iris  (
         <a class="graphic graphic_picture graphicRef56332" href="/z/d/graphic/56332.html" rel="external">
          picture 4B
         </a>
         ) is the most frequent site of ocular involvement, but the lid  (
         <a class="graphic graphic_picture graphicRef75895" href="/z/d/graphic/75895.html" rel="external">
          picture 4A
         </a>
         ), orbit, ciliary body, cornea, and episclera may also be affected. Red eye and hyphema (bleeding into the anterior chamber of the eye) are the most common presenting complaints. Uveitis, heterochromia iridis, or iris masses  (
         <a class="graphic graphic_picture graphicRef56332" href="/z/d/graphic/56332.html" rel="external">
          picture 4B
         </a>
         ) can also occur [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Secondary unilateral glaucoma can occur as a result of an acute rise in intraocular pressure from mass effect of blood or the JXG itself and can cause blindness (see
         <a class="medical medical_review" href="/z/d/html/6272.html" rel="external">
          "Overview of glaucoma in infants and children", section on 'Secondary glaucoma'
         </a>
         ). Posterior segment involvement is rare [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3805954371">
         <span class="h1">
          CLINICAL COURSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         JXG generally follows a benign course. Spontaneous regression is the rule for skin lesions and occurs in approximately one to five years [
         <a href="#rid13">
          13
         </a>
         ], sometimes leaving an atrophic or hyperpigmented scar. Extracutaneous and systemic JXGs also spontaneously regress in most cases.
        </p>
        <p>
         Congenital JXG with multisystem or extensive visceral involvement may require aggressive treatment, as fatalities may occur in up to 20 percent of cases [
         <a href="#rid3">
          3,5,8
         </a>
         ]. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H432992837">
         <span class="h1">
          ASSOCIATED CONDITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         JXG has been reported in approximately 3 to 10 percent of patients with neurofibromatosis type 1 (NF1) and in approximately 30 percent of NF1 patients younger than two years [
         <a href="#rid22">
          22-24
         </a>
         ]. In young children, the presence of multiple café-au-lait macules and JXG may be a marker of NF1 even in the absence of other reliable diagnostic signs of NF1 [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
         An association between JXG, NF1, and juvenile myelomonocytic leukemia (a rare form of childhood leukemia) has been described in a few single case reports [
         <a href="#rid25">
          25-32
         </a>
         ]. However, the clinical implications of this triple association are unclear [
         <a href="#rid22">
          22,33
         </a>
         ]. In a large, retrospective, case-control study of 739 patients with NF1, those who had JXGs were not found to have an increased risk of any malignancies compared with those without JXGs (odds ratio 1.5, 95% CI 0.35-6.6, p = 0.56) [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia", section on 'Juvenile myelomonocytic leukemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12028603">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis of JXG is in most cases made clinically, based on the typical appearance of lesions on physical examination. Biopsy is infrequently performed because the clinical picture is usually so typical and because of the self-healing nature of the disease. When the diagnosis is in doubt, skin biopsy for histology and immunostaining is necessary. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
         Dermoscopy has been suggested as a potentially useful tool for the diagnosis of JXG. The most characteristic dermoscopic finding in early to fully developed JXG is the so-called "setting sun" sign, which consists of a yellow-orange, central area surrounded by a peripheral, pink border with fine, branched, linear telangiectasias. In older lesions that contain more lipidized cells, dermoscopy shows white and yellow globules [
         <a href="#rid35">
          35,36
         </a>
         ]. Other dermoscopic features may include shiny, white streaks and irregularly distributed, heterogenous, vascular structures [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5404435">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical differential diagnosis of JXG in children includes Langerhans cell histiocytosis, other xanthomatous lesions, mastocytoma, Spitz nevus, and dermatofibroma. In most cases, the histologic features and immunohistochemistry staining are diagnostic  (
         <a class="graphic graphic_table graphicRef59870" href="/z/d/graphic/59870.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Langerhans cell histiocytosis
         </strong>
         – Langerhans cell histiocytosis typically presents in infancy as a refractory seborrheic dermatitis, a recalcitrant diaper dermatitis with ulcerations and erosions, or an eruption of cutaneous papules and nodules  (
         <a class="graphic graphic_picture graphicRef69504" href="/z/d/graphic/69504.html" rel="external">
          picture 5
         </a>
         ). Arginine vasopressin deficiency (central diabetes insipidus), hepatosplenomegaly, lymphadenopathy, and bone marrow involvement can occur. Individual lesions are typically smaller than those of JXG. On immunostaining of biopsied tissue, Langerhans cell histiocytosis is S100 and CD1a positive, but JXG is S100 and CD1a negative. (See
         <a class="medical medical_review" href="/z/d/html/8385.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Skin and oral mucosa'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other xanthomatous lesions
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Xanthoma disseminatum
         </strong>
         – Xanthoma disseminatum is a rare, nonfamilial form of non-Langerhans cell histiocytosis occurring in young adults, with frequent involvement of mucocutaneous sites [
         <a href="#rid38">
          38,39
         </a>
         ]. It is often associated with arginine vasopressin deficiency (central diabetes insipidus). Numerous erythematous, yellow-brown papules and nodules are symmetrically distributed on the trunk, face, and upper extremities  (
         <a class="graphic graphic_picture graphicRef116609" href="/z/d/graphic/116609.html" rel="external">
          picture 6
         </a>
         ). Lesions may become confluent in flexural areas [
         <a href="#rid40">
          40
         </a>
         ]. The histologic and immunohistochemical characteristics are the same as JXG.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Papular xanthoma
         </strong>
         – Papular xanthoma  (
         <a class="graphic graphic_picture graphicRef72187" href="/z/d/graphic/72187.html" rel="external">
          picture 7
         </a>
         ) is a very uncommon disease that occurs mainly in normolipidemic adults and presents as multiple yellow or red papules or nodules on the trunk and, less frequently, on the head and extremities. Rare pediatric cases have been reported [
         <a href="#rid41">
          41-44
         </a>
         ]. The histologic and immunohistochemical differentiation from JXG is difficult. Papular xanthoma presents with a dense infiltrate of foam cells, with fewer Touton cells and inflammatory cells than JXG. Immunostaining for factor XIIIa was negative in a series of 10 cases [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Eruptive xanthomas
         </strong>
         – Eruptive xanthomas occur in adults in the setting of hypertriglyceridemia, as crops of tiny, yellowish-red papules on a background of erythema  (
         <a class="graphic graphic_picture graphicRef62471" href="/z/d/graphic/62471.html" rel="external">
          picture 8
         </a>
         ). Sites of predilection include the buttocks, shoulders, and extensor extremities. Facial and oral involvement can occur. Histologically, eruptive xanthoma consists of a dermal infiltrate of histiocytes, lymphocytes, neutrophils, and, in mature lesions, small foam cells. (See
         <a class="medical medical_review" href="/z/d/html/13786.html" rel="external">
          "Cutaneous xanthomas", section on 'Eruptive xanthomas'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tuberous xanthoma
         </strong>
         – Tuberous xanthomas occur most often in areas of pressure, such as the buttocks, knees  (
         <a class="graphic graphic_picture graphicRef104995" href="/z/d/graphic/104995.html" rel="external">
          picture 9
         </a>
         ), and elbows  (
         <a class="graphic graphic_picture graphicRef72875 graphicRef104996" href="/z/d/graphic/72875.html" rel="external">
          picture 10A-B
         </a>
         ). They are firm, asymptomatic, reddish-yellow nodules, seen in patients with hypercholesterolemia and high low-density lipoprotein. Histologically, tuberous xanthoma consists of dermal aggregates of foam cells, with absence of Touton cells or other inflammatory cells. (See
         <a class="medical medical_review" href="/z/d/html/13786.html" rel="external">
          "Cutaneous xanthomas", section on 'Tuberous xanthomas'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Spitz nevus
         </strong>
         – Spitz nevi present as a single, dome-shaped, pink to red or dark-brown papule on the face or extremities of children. Histologically, classic Spitz nevi show a symmetrical proliferation of spindle and epithelioid cells, often in nests. Immunostaining confirms the melanocytic origin (S100, Melan-A [Mart-1], and tyrosinase positive) [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13523.html" rel="external">
          "Spitz nevus and atypical Spitz tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mastocytoma
         </strong>
         – Mastocytomas are benign collections of mast cells within the dermis that demonstrate urtication (wheal formation) with stroking (Darier sign). They are relatively common in children and appear as reddish to golden brown papules or plaques, which can sometimes have a rubbery feel  (
         <a class="graphic graphic_picture graphicRef80221 graphicRef50284" href="/z/d/graphic/80221.html" rel="external">
          picture 11A-B
         </a>
         ). They are generally asymptomatic but can be mildly pruritic with urtication. Pathology shows mast cells in the papillary dermis highlighted by Giemsa stain. (See
         <a class="medical medical_review" href="/z/d/html/103161.html" rel="external">
          "Mastocytosis (cutaneous and systemic) in children: Epidemiology, clinical manifestations, evaluation, and diagnosis", section on 'Skin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dermatofibroma
         </strong>
         – Dermatofibromas are benign, generally asymptomatic, tan to reddish-brown papules seen frequently on the extremities. They often arise after minor inflammation or trauma (eg, folliculitis or insect bite). They are seen more commonly in older children and adults than in infants. Histologically, an acanthotic epidermis with an underlying zone of normal papillary dermis is seen. The lesion is unencapsulated, and collagen trapping (spindle cells encasing normal collagen) occurs at the periphery. Spindle cells overlap in fascicles and whorls. (See
         <a class="medical medical_review" href="/z/d/html/5573.html" rel="external">
          "Overview of benign lesions of the skin", section on 'Dermatofibroma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12028610">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of JXG depends on the site(s) of involvement.
        </p>
        <p class="headingAnchor" id="H21221319">
         <span class="h2">
          Cutaneous juvenile xanthogranuloma
         </span>
         <span class="headingEndMark">
          —
         </span>
         No treatment is needed for cutaneous JXG. Reassurance to patients and the parents/caregivers of affected children about the benign course and spontaneous regression of the disease is usually all that is necessary. Involution usually occurs one to five years after onset [
         <a href="#rid46">
          46
         </a>
         ]. Most resolve without scarring, though atrophic scarring is possible and likely more common in larger lesions.
        </p>
        <p>
         Routine referral of all patients with cutaneous JXG for ophthalmologic evaluation is not recommended [
         <a href="#rid4">
          4
         </a>
         ]. Most patients with ocular involvement present with acute ocular complaints; asymptomatic eye involvement is rare.
        </p>
        <p>
         However, it is reasonable to consider referral to ophthalmology for patients under age 2 presenting with multiple micronodular (&lt;10 mm) JXGs, as they may have a higher risk of ocular involvement [
         <a href="#rid4">
          4
         </a>
         ], though yield of routine eye examination is low in the absence of ocular complaints or signs [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21221326">
         <span class="h2">
          Subcutaneous and soft tissue juvenile xanthogranuloma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subcutaneous and soft tissue lesions also resolve spontaneously and do not require treatment.
        </p>
        <p class="headingAnchor" id="H21221333">
         <span class="h2">
          Ocular juvenile xanthogranuloma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with ocular and periocular lesions should be referred to an ophthalmologist for diagnosis confirmation and management. The treatment depends on the type of ocular involvement and complications [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21221340">
         <span class="h2">
          Symptomatic systemic juvenile xanthogranuloma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic lesions that are associated with symptoms (eg, mass effect) may require treatment if they do not spontaneously regress [
         <a href="#rid18">
          18
         </a>
         ]. Treatment decisions for patients with symptomatic systemic JXG should be made on a case-by-case basis. Referral to an oncologist may be warranted. Treatment may involve excision, radiotherapy, and/or systemic chemotherapy [
         <a href="#rid47">
          47-51
         </a>
         ].
        </p>
        <p>
         There is no standard chemotherapeutic regimen for systemic JXG. A variety of regimens have been tried with variable results [
         <a href="#rid47">
          47
         </a>
         ]. Most of these regimens included agents that are used in the treatment of Langerhans cell histiocytosis (eg,
         <a class="drug drug_pediatric" data-topicid="12881" href="/z/d/drug information/12881.html" rel="external">
          vinblastine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          mercaptopurine
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16627.html" rel="external">
          "Treatment of non-pulmonary Langerhans cell histiocytosis"
         </a>
         .)
        </p>
        <p>
         Central nervous system involvement has been successfully treated with
         <a class="drug drug_pediatric" data-topicid="13164" href="/z/d/drug information/13164.html" rel="external">
          cladribine
         </a>
         (2-chlorodeoxyadenosine) [
         <a href="#rid52">
          52-54
         </a>
         ]. In one patient, extracutaneous JXG was successfully treated with
         <a class="drug drug_pediatric" data-topicid="13090" href="/z/d/drug information/13090.html" rel="external">
          thalidomide
         </a>
         after failure of other chemotherapeutic regimens [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12028617">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prognosis of cutaneous JXG is uniformly good; spontaneous regression of skin lesions over a few years is the rule. Patients may have residual hyperpigmentation, minimal atrophy, or anetoderma (loss of elastic fibers in the dermis) following regression [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Extracutaneous JXGs most often regress spontaneously as well, although treatment may be needed to relieve symptoms due to mass effect. Long-term sequelae are rarely reported. Fatalities can occur, typically in infants with central nervous system or massive hepatic involvement and liver failure [
         <a href="#rid3">
          3,5,18,56-58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12028624">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Juvenile xanthogranuloma (JXG) is a rare, benign, proliferative, histiocytic disorder of dermal dendrocyte origin and is the most common of the non-Langerhans cell histiocytoses. It occurs predominantly in young children. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – In most cases,
         <em>
         </em>
         JXG arises in the first year of life. Infrequently, JXG may be present at birth (see
         <a class="local">
          'Age of onset and lesion distribution'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cutaneous lesions
         </strong>
         – Typical skin lesions appear as reddish to yellow papules, plaques, or nodules 0.5 to 2 cm in size, most often located on the head, neck, and upper trunk  (
         <a class="graphic graphic_picture graphicRef69122" href="/z/d/graphic/69122.html" rel="external">
          picture 1D
         </a>
         ). (See
         <a class="local">
          'Cutaneous lesions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Extracutaneous/systemic juvenile xanthogranuloma
         </strong>
         – Extracutaneous or systemic JXG is rare, occurring in up to 4 percent of all cases, and may involve every organ or system (including the eye). Ocular JXG may occur in the absence of skin lesions and usually presents with ocular manifestations (hyphema, uveitis, iris or corneal lesions)  (
         <a class="graphic graphic_picture graphicRef75895 graphicRef56332" href="/z/d/graphic/75895.html" rel="external">
          picture 4A-B
         </a>
         ). (See
         <a class="local">
          'Extracutaneous and systemic involvement'
         </a>
         above and
         <a class="local">
          'Ocular juvenile xanthogranuloma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis is clinical in most cases. In difficult cases, histology and immunohistochemistry are diagnostic. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Cutaneous JXG generally regresses spontaneously. Reassurance about the benign course is usually all that is necessary. Patients with ocular JXG should be referred to an ophthalmologist. Systemic JXG may require treatment (excision, radiotherapy, and/or chemotherapy) if it causes symptoms. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H712471299">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Kate B Püttgen, MD, FAAD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           So N, Liu R, Hogeling M. Juvenile xanthogranulomas: Examining single, multiple, and extracutaneous presentations. Pediatr Dermatol 2020; 37:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer 2005; 45:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janssen D, Harms D. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry. Am J Surg Pathol 2005; 29:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang MW, Frieden IJ, Good W. The risk intraocular juvenile xanthogranuloma: survey of current practices and assessment of risk. J Am Acad Dermatol 1996; 34:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dehner LP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 2003; 27:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caputo R, Marzano AV, Passoni E, Berti E. Unusual variants of non-Langerhans cell histiocytoses. J Am Acad Dermatol 2007; 57:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paxton CN, O'Malley DP, Bellizzi AM, et al. Genetic evaluation of juvenile xanthogranuloma: genomic abnormalities are uncommon in solitary lesions, advanced cases may show more complexity. Mod Pathol 2017; 30:1234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu J, Huang X, Wen Y, et al. Systemic juvenile xanthogranuloma has a higher frequency of ALK translocations than BRAFV600E mutations. J Am Acad Dermatol 2023; 88:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diamond EL, Durham BH, Haroche J, et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov 2016; 6:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez-Martin A, Baselga E, Drolet BA, Esterly NB. Juvenile xanthogranuloma. J Am Acad Dermatol 1997; 36:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salari B, Dehner LP. Juvenile Xanthogranuloma: A Comparative Immunohistochemical Study of Factor XIIIa, CD11c, and CD4. Am J Dermatopathol 2022; 44:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wee LWY, Ling HY, Ho VPY, et al. Juvenile xanthogranulomas in Asian children. Dermatol Ther 2022; 35:e15224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isaacs H Jr. Fetal and neonatal histiocytoses. Pediatr Blood Cancer 2006; 47:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kundak S, Çakır Y. Juvenile xanthogranuloma: retrospective analysis of 44 pediatric cases (single tertiary care center experience). Int J Dermatol 2021; 60:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oza VS, Stringer T, Campbell C, et al. Congenital-type juvenile xanthogranuloma: A case series and literature review. Pediatr Dermatol 2018; 35:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuelov L, Kinori M, Chamlin SL, et al. Risk of intraocular and other extracutaneous involvement in patients with cutaneous juvenile xanthogranuloma. Pediatr Dermatol 2018; 35:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zou T, Wei A, Ma H, et al. Systemic juvenile xanthogranuloma: A systematic review. Pediatr Blood Cancer 2023; 70:e30232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freyer DR, Kennedy R, Bostrom BC, et al. Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr 1996; 129:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samara WA, Khoo CT, Say EA, et al. Juvenile Xanthogranuloma Involving the Eye and Ocular Adnexa: Tumor Control, Visual Outcomes, and Globe Salvage in 30 Patients. Ophthalmology 2015; 122:2130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vendal Z, Walton D, Chen T. Glaucoma in juvenile xanthogranuloma. Semin Ophthalmol 2006; 21:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SANDERS TE. Intraocular juvenile xanthogranuloma (nevoxanthogranuloma): a survey of 20 cases. Trans Am Ophthalmol Soc 1960; 58:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cambiaghi S, Restano L, Caputo R. Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies. Pediatr Dermatol 2004; 21:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrari F, Masurel A, Olivier-Faivre L, Vabres P. Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1. JAMA Dermatol 2014; 150:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miraglia E, Laghi A, Moramarco A, Giustini S. Juvenile xanthogranuloma in neurofibromatosis type 1. Prevalence and possible correlation with lymphoproliferative diseases: experience of a single center and review of the literature. Clin Ter 2022; 173:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fenot M, Stalder JF, Barbarot S. Juvenile xanthogranulomas are highly prevalent but transient in young children with neurofibromatosis type 1. J Am Acad Dermatol 2014; 71:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raygada M, Arthur DC, Wayne AS, et al. Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia. Pediatr Blood Cancer 2010; 54:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin HT, Harris MB, Orlow SJ. Juvenile myelomonocytic leukemia presenting with features of hemophagocytic lymphohistiocytosis in association with neurofibromatosis and juvenile xanthogranulomas. J Pediatr Hematol Oncol 2004; 26:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benessahraoui M, Aubin F, Paratte F, et al. [Juvenile myelomonocytic leukaemia, xanthoma, and neurofibromatosis type 1]. Arch Pediatr 2003; 10:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larrègue M, Belaïch S, Delzant O, Degos R. [Xanthomatoleukemia in young children and Recklinghausen's disease]. Ann Dermatol Syphiligr (Paris) 1972; 99:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Royer P, Blondet C. Xantholeucemie du nourrisson et neurofibromatose de Recklinghausen. Ann Pediatr (Paris) 1958; 24:1504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paulus S, Koronowska S, Fölster-Holst R. Association Between Juvenile Myelomonocytic Leukemia, Juvenile Xanthogranulomas and Neurofibromatosis Type 1: Case Report and Review of the Literature. Pediatr Dermatol 2017; 34:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miraglia E, Fino P, Calvieri S, Giustini S. Juvenile myelomonocytic leukemia in a patient with neurofibromatosis type 1 and xanthogranulomas. G Ital Dermatol Venereol 2019; 154:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgdorf WH, Zelger B. JXG, NF1, and JMML: alphabet soup or a clinical issue? Pediatr Dermatol 2004; 21:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liy-Wong C, Mohammed J, Carleton A, et al. The relationship between neurofibromatosis type 1, juvenile xanthogranuloma, and malignancy: A retrospective case-control study. J Am Acad Dermatol 2017; 76:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song M, Kim SH, Jung DS, et al. Structural correlations between dermoscopic and histopathological features of juvenile xanthogranuloma. J Eur Acad Dermatol Venereol 2011; 25:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu J, Ma L. Dermoscopic Patterns in Juvenile Xanthogranuloma Based on the Histological Classification. Front Med (Lausanne) 2020; 7:618946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peruilh-Bagolini L, Silva-Astorga M, Hernández San Martín MJ, et al. Dermoscopy of Juvenile Xanthogranuloma. Dermatology 2021; 237:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caputo R, Veraldi S, Grimalt R, et al. The various clinical patterns of xanthoma disseminatum. Considerations on seven cases and review of the literature. Dermatology 1995; 190:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park M, Boone B, Devos S. Xanthoma disseminatum: case report and mini-review of the literature. Acta Dermatovenerol Croat 2014; 22:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gong HZ, Zheng HY, Li J. Xanthoma disseminatum. Lancet 2018; 391:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breier F, Zelger B, Reiter H, et al. Papular xanthoma: a clinicopathological study of 10 cases. J Cutan Pathol 2002; 29:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CG, Chen CL, Liu HN. Primary papular xanthoma of children: a clinicopathologic, immunohistopathologic and ultrastructural study. Am J Dermatopathol 1997; 19:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonseca E, Contreras F, Cuevas J. Papular xanthoma in children: report and immunohistochemical study. Pediatr Dermatol 1993; 10:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caputo R, Gianni E, Imondi D, et al. Papular xanthoma in children. J Am Acad Dermatol 1990; 22:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busam KJ, Granter SR, Iversen K, Jungbluth AA. Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi. Am J Dermatopathol 2000; 22:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gianotti F, Caputo R. Histiocytic syndromes: a review. J Am Acad Dermatol 1985; 13:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stover DG, Alapati S, Regueira O, et al. Treatment of juvenile xanthogranuloma. Pediatr Blood Cancer 2008; 51:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakasu S, Tsuji A, Fuse I, Hirai H. Intracranial solitary juvenile xanthogranuloma successfully treated with stereotactic radiosurgery. J Neurooncol 2007; 84:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Paula AM, André N, Fernandez C, et al. Solitary, extracutaneous, skull-based juvenile xanthogranuloma. Pediatr Blood Cancer 2010; 55:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller RP, Busse H. [Radiotherapy in juvenile xanthogranuloma of the iris]. Klin Monbl Augenheilkd 1986; 189:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang B, Jin H, Zhao Y, Ma J. The clinical diagnosis and management options for intracranial juvenile xanthogranuloma in children: based on four cases and another 39 patients in the literature. Acta Neurochir (Wien) 2016; 158:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajendra B, Duncan A, Parslew R, Pizer BL. Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. Pediatr Blood Cancer 2009; 52:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maintz L, Wenzel J, Irnich M, et al. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine: case report and review of the literature. Br J Dermatol 2017; 176:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsukawa Y, Sakamoto K, Shioda Y. Refractory Extracutaneous Juvenile Xanthogranuloma With Multiple Intracranial Nodular Lesions Successfully Treated With 2-Chlorodeoxyadenosine. J Pediatr Hematol Oncol 2022; 44:e823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailey KM, Castle VP, Hummel JM, et al. Thalidomide therapy for aggressive histiocytic lesions in the pediatric population. J Pediatr Hematol Oncol 2012; 34:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azorín D, Torrelo A, Lassaletta A, et al. Systemic juvenile xanthogranuloma with fatal outcome. Pediatr Dermatol 2009; 26:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orsey A, Paessler M, Lange BJ, Nichols KE. Central nervous system juvenile xanthogranuloma with malignant transformation. Pediatr Blood Cancer 2008; 50:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu WK, Gilliam AC, Wiersma SR, Dahms BB. Fatal congenital systemic juvenile xanthogranuloma with liver failure. Pediatr Dev Pathol 2004; 7:71.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13729 Version 17.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32468628" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Juvenile xanthogranulomas: Examining single, multiple, and extracutaneous presentations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15547923" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15613853" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8609257" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The risk intraocular juvenile xanthogranuloma: survey of current practices and assessment of risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12717244" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17485142" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Unusual variants of non-Langerhans cell histiocytoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28752840" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Genetic evaluation of juvenile xanthogranuloma: genomic abnormalities are uncommon in solitary lesions, advanced cases may show more complexity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32822792" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Systemic juvenile xanthogranuloma has a higher frequency of ALK translocations than BRAFV600E mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26566875" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9091465" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Juvenile xanthogranuloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35315372" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Juvenile Xanthogranuloma: A Comparative Immunohistochemical Study of Factor XIIIa, CD11c, and CD4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34820973" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Juvenile xanthogranulomas in Asian children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16416419" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Fetal and neonatal histiocytoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33301172" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Juvenile xanthogranuloma: retrospective analysis of 44 pediatric cases (single tertiary care center experience).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29999209" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Congenital-type juvenile xanthogranuloma: A case series and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29488239" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Risk of intraocular and other extracutaneous involvement in patients with cutaneous juvenile xanthogranuloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36779547" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Systemic juvenile xanthogranuloma: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8765620" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Juvenile xanthogranuloma: forms of systemic disease and their clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26189188" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Juvenile Xanthogranuloma Involving the Eye and Ocular Adnexa: Tumor Control, Visual Outcomes, and Globe Salvage in 30 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912017" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Glaucoma in juvenile xanthogranuloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13746162" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Intraocular juvenile xanthogranuloma (nevoxanthogranuloma): a survey of 20 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15078345" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24258576" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35857053" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Juvenile xanthogranuloma in neurofibromatosis type 1. Prevalence and possible correlation with lymphoproliferative diseases: experience of a single center and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25037786" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Juvenile xanthogranulomas are highly prevalent but transient in young children with neurofibromatosis type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19785027" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15342987" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Juvenile myelomonocytic leukemia presenting with features of hemophagocytic lymphohistiocytosis in association with neurofibromatosis and juvenile xanthogranulomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14550978" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : [Juvenile myelomonocytic leukaemia, xanthoma, and neurofibromatosis type 1].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4633707" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : [Xanthomatoleukemia in young children and Recklinghausen's disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Xantholeucemie du nourrisson et neurofibromatose de Recklinghausen
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28111791" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Association Between Juvenile Myelomonocytic Leukemia, Juvenile Xanthogranulomas and Neurofibromatosis Type 1: Case Report and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29600694" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Juvenile myelomonocytic leukemia in a patient with neurofibromatosis type 1 and xanthogranulomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15078363" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : JXG, NF1, and JMML: alphabet soup or a clinical issue?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28189268" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The relationship between neurofibromatosis type 1, juvenile xanthogranuloma, and malignancy: A retrospective case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20698915" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Structural correlations between dermoscopic and histopathological features of juvenile xanthogranuloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33521026" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Dermoscopic Patterns in Juvenile Xanthogranuloma Based on the Histological Classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33075787" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Dermoscopy of Juvenile Xanthogranuloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7894090" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The various clinical patterns of xanthoma disseminatum. Considerations on seven cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25102803" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Xanthoma disseminatum: case report and mini-review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29031846" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Xanthoma disseminatum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12028152" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Papular xanthoma: a clinicopathological study of 10 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9415617" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Primary papular xanthoma of children: a clinicopathologic, immunohistopathologic and ultrastructural study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8346106" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Papular xanthoma in children: report and immunohistochemical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2115054" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Papular xanthoma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10871066" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3932492" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Histiocytic syndromes: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18338395" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Treatment of juvenile xanthogranuloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17332947" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Intracranial solitary juvenile xanthogranuloma successfully treated with stereotactic radiosurgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20582967" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Solitary, extracutaneous, skull-based juvenile xanthogranuloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3093751" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : [Radiotherapy in juvenile xanthogranuloma of the iris].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27173098" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The clinical diagnosis and management options for intracranial juvenile xanthogranuloma in children: based on four cases and another 39 patients in the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18989881" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27312940" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34486561" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Refractory Extracutaneous Juvenile Xanthogranuloma With Multiple Intracranial Nodular Lesions Successfully Treated With 2-Chlorodeoxyadenosine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22810753" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Thalidomide therapy for aggressive histiocytic lesions in the pediatric population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20199446" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Systemic juvenile xanthogranuloma with fatal outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17520744" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Central nervous system juvenile xanthogranuloma with malignant transformation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15255037" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Fatal congenital systemic juvenile xanthogranuloma with liver failure.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
